Latest Articlesddd

Developing Another Better CAR Using NK Cells Instead of T Cells. Nektar Has Great News

July 19, 2017 0

IMPROVING ON CAR IMMUNOTHERAPY APPROACH  When we stated that chimeric antigen receptor CAR immunotherapy process was …

The Meaning of a 10-0 Vote in Favor of Novartis’ CAR T-Cell Therapy Approval.

July 13, 2017 0

A BIG YES for Novartis CAR-T product has come from the  Food and Drug Administration (FDA) advisory …

Arena’s Successful Pulmonary Arterial Hypertension Drug. Novartis CAR-T Product Review for Approval Tomorrow

July 11, 2017 0

Arena (ARNA) announced positive Phase 2 clinical trial results for its drug ralinepag1 for pulmonary arterial hypertension …

Targeted Drugs That Would Improve on Immunotherapy Treatments’ Outcomes. See Array and Exelixis

July 10, 2017 0

FROM ARRAY Array’s Drug Binimetinib in Combination Therapy with Merck’s Drug Keytruda for METASTATIC FOR COLORECTAL …

Celgene and Immunotherapy: An Unfolding Story

July 8, 2017 0

As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the …

Merck’s Keytruda: Extremely Valuable, But Not for Multiple Myeloma

July 6, 2017 0

Merck’s (MRK) anti-PD-1 drug Keytruda® (pembrolizumab) is approved for many, many cancers. Yet, it is fair …

About Old Drugs and New Drugs, Large Companies and Small Companies

July 3, 2017 0

Additional Combination Treatment with Vectibix  for Metastatic Colorectal Cancer (mCRC) The Old Drug: VECTIBIX     …

Halozyme’s Approved Drug, Promising News and Ongoing Pancreatic Cancer Trials

June 30, 2017 0

On June 22, 2017, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan Hycela™. …

Portola’s Next Moves and Its Upcoming Approval

June 28, 2017 0

The most important last barrier to cross or dismantle for drug developers is the approval of …

About Bellicum Pharmaceuticals’ Product BPX-501

June 27, 2017 0

IMPRESSIVE RESULTS?  Bellicum Pharmaceuticals’ (BLCM) drug BPX-501 is described as a safe and effective product that …

Congratulations: The FDA Approved Portola’s Anticoagulant Drug Bevyxxa (betrixaban). The Stock Rallied.

June 23, 2017 0

Portola (PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the …

The Biotech Rally, the New FDA Commissioner and the Companies That Would Benefit

June 23, 2017 0

We examined many explanations about the rallying in the biotech stocks, including the reports stating that …

Prohost Letter #411

June 21, 2017 0

Prohost Letter #411 SOME STOCK RALLYING NEWS - Under normal conditions, some good news should rally …

Can the Changes Rejuvenate Regulus’ Stock? Alport Syndrome Investigational Drug Advances in Trials

June 19, 2017 0

Since Regulus’ (RGLS) lead candidate drug RG101 for HCV was put on clinical hold by the …

Prohost Letter #410

June 13, 2017 0

Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of …

Juno Also has Great News from Its CAR-T Cell Approach

June 8, 2017 0

Juno’s (JUNO) JCAR017 and JCAR014 are chimeric antigen receptor T cell (CAR-T) product candidates that target …

Bluebird Flies Sky-High with Its CAR-T Wings

June 7, 2017 0

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was …

Data From ASCO and Data from the Internet

June 6, 2017 0

As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology …

FDA Breakthrough Therapy Designation for Alnylam’s RNAi Drug Givosiran

June 2, 2017 0

Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the …

CAR-T Great News and About the Biotech Sector in General

June 1, 2017 0

It is obvious that the CAR-T approach to cancer treatment is here to stay and to …